• Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis
• Sandoz has begun shipping to US customers following recent FDA approval
• Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services

Holzkirchen, Germany, June 18, 2015 – Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva’s Copaxone® (glatiramer acetate …

• Strong progress on innovation across divisions
  • Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and CART with immuno-oncology assets
  • Alcon is focused on eye care innovation, including strengthening its IOL pipeline over prior year and focusing on early-stage discovery in Ophthalmic Pharmaceuticals
  • Sandoz is extending its lead in differentiated generics, exemplified by first-of-a-kind FDA approvals for biosimilar Zarxio and generic Copaxone® 20mg …